<DOC>
	<DOCNO>NCT02571959</DOCNO>
	<brief_summary>Description pharmacokinetic parameter amoxicillin / clavulanic acid healthy voluntary obese oral intra venous administration Determination pharmacokinetic parameter amoxicillin / clavulanic acid obtain plasmatic concentration intravenous injection ( IV ) oral administration . The criterion evaluation allow answer main objective corresponds parameter estimate pharmacokinetic model concentration obtain data IV pharmacokinetic model concentration obtain oral data . The following pharmacokinetic parameter consider every obese volunteer 's molecule ( amoxicillin clavulanic acid ) concentration pharmacokinetic analysis population . The main evaluation criterion PK parameter amoxicillin / clavulanic : - Cl , systematic plasmatic clearance - Vd , volume distribution - ASC 0-oo , area curve time - concentration - T1/2 , half-life time - F , bioavailability oral administration - Ka , constant speed absorption</brief_summary>
	<brief_title>Pharmacokinetic Study Association Amoxicillin / Clavulanic Acid Obese Adults</brief_title>
	<detailed_description>Main objective Description pharmacokinetic parameter amoxicillin / clavulanic acid healthy voluntary obese oral intra venous administration Secondary objectives - Define dosage plan optimize antibiotic treatment obese subject - Ensure adequacy treatment related infection - Formulate recommendation dosage adaptation good individualization treatment , estimate several plan dos simulation reach various PK/PD goal accord different theoretical MIC Methodology The pharmacokinetic analysis realize approach population allow estimation average parameter amoxicillin clavulanic acid well interpersonal variability administration IV oral administration . Parameters 's population variability estimate SAEM algorithm implement software Monolix ( www.lixoft.eu ) . For main objective , PK parameter PK amoxicillin clavulanic acid determine day 1 day 2 . They describe mean indicator position ( average median ) dispersal ( standard deviation , quartile ) . For secondary objective , profile concentration/time 1000 obese subject determine Monte Carlo method PK parameter estimate balance model . For every feign profile , time plasmatic concentration amoxicillin clavulanic acid superior panel theoretical MIC calculate mean curve concentration - time determined subject .</detailed_description>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<criteria>Voluntary obese Body mass index upper 30 kg/m2 Age 18 65 year Signed free lit consent Possible participation accord national file volunteer French Ministry Health . Volunteers affiliate Social Security Pregnancy Evolutionary pregnancy feed Allergy ßlactamines ( nettle rash , oedema Quincke ) Digestive intolerance amoxicillin / clavulanic acid Infection virus HIV ( positive Ac anti HIV ) Infection virus hepatitis B ( positive Ag Hbs ) Infection virus hepatitis C ( positive Ac anti VHC ) Hepatic cirrhosis ChildPugh C stage ( stadium ) Biological parameter : Polynucléaires neutrophiles 750 / mm3 Haemoglobin 8g / dL Patellets 60 000 / mm3 Creatinin clearance , accord MDRD , DFG 50 mL / min / 1,73m2 ASAT ALAT &gt; 3 time superior limit normal ( LSN ) Phosphatase alkaline &gt; 3 LSN Total Bilirubine &gt; 3 LSN Lipase &gt; 3 LSN Factor V &lt; 50 % Alcoholism chronicle ( consumption superior 30 g alcohol day , amount 3 glass wine ) Significant anomaly electrocardiogram , particular QTc &gt; 450 msec Subject susceptible respect modality study Drug addiction intra venous Any medical condition accord judgment ( sentence ) investigator would may interfere moderate pharmacokinetic parameter People place legal protection Histories bariatric surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Amoxicillin-Potassium Clavulanate Combination</keyword>
</DOC>